Latest Biotechnology News

Starpharma has secured two major partnership agreements with Genentech and Radiopharm Theranostics, unlocking significant upfront payments and milestone potential while advancing its clinical pipeline.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.

Memphasys has signed a pivotal supply agreement with Andro Diagnostics to distribute its Felix™ sperm separation system across over 200 IVF clinics in India, marking a major step in its new global go-direct commercial strategy.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

Clarity Pharmaceuticals has responded to ASX queries clarifying the timing and materiality of its SAR-bisFAP data presentation, denying the information was price sensitive despite a notable share price rise.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Proteomics International Laboratories has secured ISO 15189 certification and launched PromarkerD and PromarkerEso nationally in Australia, while advancing US reimbursement pathways and preparing for leadership transition.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting genetic diseases, alongside a strong cash runway supporting ongoing development.

AdAlta Limited has fully repaid its remaining NLSC investment in cash, ending its obligation to issue further shares and positioning itself for private capital raises to advance its CAR-T therapies.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.